Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Intangibles (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Intangibles for 3 consecutive years, with $322.5 million as the latest value for Q1 2025.

  • On a quarterly basis, Intangibles changed N/A to $322.5 million in Q1 2025 year-over-year; TTM through Mar 2025 was $322.5 million, a N/A change, with the full-year FY2024 number at $313.1 million, changed N/A from a year prior.
  • Intangibles was $322.5 million for Q1 2025 at Iovance Biotherapeutics, up from $313.1 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $322.5 million in Q1 2025 to a low of $235.5 million in Q2 2023.
  • A 3-year average of $290.4 million and a median of $313.1 million in 2024 define the central range for Intangibles.